Literature DB >> 22183933

Pencil-thin ependymal enhancement in neuromyelitis optica spectrum disorders.

Piyush Banker1, Smitha Sonni, Ilya Kister, John P Loh, Yvonne W Lui.   

Abstract

AQP4 water channels are thought to be the target of autoimmune attack in neuromyelitis optica-spectrum disorders (NMOsd). AQP4 are highly expressed on ventricular ependyma. The objective of this study was to describe a novel pattern of linear, 'pencil-thin' enhancement of ventricular ependyma in NMOsd. We report two NMOsd patients with pencil-thin ependymal enhancement along the frontal and occipital horns of lateral ventricles. Differential diagnosis of ependymal enhancement should include NMOsd alongside with infectious and neoplastic etiologies. Pencil-thin ependymal enhancement may be a helpful radiological marker of NMOsd that can be used to differentiate this condition from multiple sclerosis.

Entities:  

Mesh：

Year:  2011        PMID： 22183933     DOI： 10.1177/1352458511431730

Source DB:  PubMed          Journal:  Mult Scler        ISSN： 1352-4585            Impact factor:   6.312


  15 in total

Review 1.  The current role of MRI in differentiating multiple sclerosis from its imaging mimics.

Authors:  Ruth Geraldes; Olga Ciccarelli; Frederik Barkhof; Nicola De Stefano; Christian Enzinger; Massimo Filippi; Monika Hofer; Friedemann Paul; Paolo Preziosa; Alex Rovira; Gabriele C DeLuca; Ludwig Kappos; Tarek Yousry; Franz Fazekas; Jette Frederiksen; Claudio Gasperini; Jaume Sastre-Garriga; Nikos Evangelou; Jacqueline Palace
Journal:  Nat Rev Neurol       Date:  2018-03-09       Impact factor: 42.937

2.  Brain MRI Findings in Pediatric-Onset Neuromyelitis Optica Spectrum Disorder: Challenges in Differentiation from Acute Disseminated Encephalomyelitis.

Authors:  E Bulut; J Karakaya; S Salama; M Levy; T A G M Huisman; I Izbudak
Journal:  AJNR Am J Neuroradiol       Date:  2019-03-07       Impact factor: 3.825

3.  Differentiating neuromyelitis optica from other causes of longitudinally extensive transverse myelitis on spinal magnetic resonance imaging.

Authors:  Yeliz Pekcevik; Charles H Mitchell; Maureen A Mealy; Gunes Orman; In H Lee; Scott D Newsome; Carol B Thompson; Carlos A Pardo; Peter A Calabresi; Michael Levy; Izlem Izbudak
Journal:  Mult Scler       Date:  2015-07-24       Impact factor: 6.312

4.  Enhancing Brain Lesions during Acute Optic Neuritis and/or Longitudinally Extensive Transverse Myelitis May Portend a Higher Relapse Rate in Neuromyelitis Optica Spectrum Disorders.

Authors:  G Orman; K Y Wang; Y Pekcevik; C B Thompson; M Mealy; M Levy; I Izbudak
Journal:  AJNR Am J Neuroradiol       Date:  2017-03-16       Impact factor: 3.825

Review 5.  What do we know about brain contrast enhancement patterns in neuromyelitis optica?

Authors:  Yeliz Pekcevik; Gunes Orman; In Ho Lee; Maureen A Mealy; Michael Levy; Izlem Izbudak
Journal:  Clin Imaging       Date:  2015-07-26       Impact factor: 1.605

Review 6.  Conventional and advanced imaging in neuromyelitis optica.

Authors:  Y Barnett; I J Sutton; M Ghadiri; L Masters; R Zivadinov; M H Barnett
Journal:  AJNR Am J Neuroradiol       Date:  2013-06-13       Impact factor: 3.825

Review 7.  Neuromyelitis optica: clinical features, immunopathogenesis and treatment.

Authors:  S Jarius; B Wildemann; F Paul
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

Review 8.  Magnetic resonance imaging in neuromyelitis optica spectrum disorder.

Authors:  Laura Clarke; Simon Arnett; Kate Lilley; Jacky Liao; Sandeep Bhuta; Simon A Broadley
Journal:  Clin Exp Immunol       Date:  2021-07-06       Impact factor: 4.330

9.  Ultrahigh-Field MR (7 T) Imaging of Brain Lesions in Neuromyelitis Optica.

Authors:  Ilya Kister; Joseph Herbert; Yongxia Zhou; Yulin Ge
Journal:  Mult Scler Int       Date:  2013-01-27

10.  Periventricular lesions help differentiate neuromyelitis optica spectrum disorders from multiple sclerosis.

Authors:  Eytan Raz; John P Loh; Luca Saba; Mirza Omari; Joseph Herbert; Yvonne Lui; Ilya Kister
Journal:  Mult Scler Int       Date:  2014-02-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.